The timing, dose, and route of early nutrition support in critically ill patients have been highly controversial for years. Despite the association of a caloric deficit with adverse outcome, several recent large, randomized, controlled trials have demonstrated a prolongation of organ failure and increased muscle weakness with increasing doses of nutrition in the acute phase of critical illness. A potential explanation for the negative impact of early, full feeding on outcome is feeding-induced suppression of autophagy, a cellular repair process that is necessary to clear intracellular damage. Whether nutrition management in critically ill patients should be guided by its effects on autophagy is a topic of debate. Currently, however, autophagy cannot be monitored in clinical practice. Moreover, clinical management should be guided by high-quality randomized controlled trials, which currently do not support the use of early full nutrition support. (Nutr Clin Pract. 2018;33:339-347) 
Critically ill patients who suffer from a severe medical disease or extensive trauma or who were admitted to the intensive care unit (ICU) after major surgery are generally unable to feed themselves, leading to a low energy and protein intake. In addition, the stress-induced inflammatory and endocrine alterations induce a hypercatabolic state, with the rapid and vast wasting of lean body mass. 1 Both a nutrition deficit and wasting syndrome have been associated with adverse outcomes. [2] [3] [4] Experts have suggested that the hypercatabolism induced by critical illness can be reversed or at least attenuated by the early administration of exogenous nutrients. [5] [6] [7] Therefore, nutrition guidelines have recommended the early initiation of enteral nutrition (EN) in hemodynamically stable patients. 5, [7] [8] [9] Traditionally, EN has been the preferred route of feeding because of its lower degree of invasiveness and lower cost when compared with parenteral nutrition (PN) and for its presumed trophic effect. 10, 11 When EN is tolerated, the guidelines recommend gradually increasing the dose up to a prespecified target. However, as early EN often fails to meet that target, the question arises when to initiate supplementary PN. In this regard, the European guidelines recommended the early initiation of supplementary PN to prevent caloric and protein deficits associated with adverse outcomes in observational studies. [12] [13] [14] [15] In contrast, because PN has been associated with more complications than EN, 16 the American guidelines advocated against early PN. Observational studies, however, do not provide proof of causality. Indeed, alternatively, the improved outcome associated with higher doses of artificial nutrition, especially with early EN, could be explained by an increased feeding tolerance in less sick patients. Moreover, other observational studies have associated the delivery of higher amounts of nutrients with adverse outcomes. 17, 18 Recently, several large randomized controlled trials (RCTs) have challenged the guidelines and have investigated whether providing full nutrition in the acute phase of critical illness is indeed beneficial (Table 1) . We review the most recent feeding RCTs in critically ill patients and discuss the potential mechanisms explaining the outcome differences, with a focus on the role of autophagy.
Results From Recent Feeding RCTs
A total of 6 RCTs have investigated whether the early administration of PN supplementing insufficient EN benefits ICU patients when compared with a later initiation of PN (Table 1) . [19] [20] [21] [22] [23] 68 In contrast to the expectations, the 2 largest RCTs, the Early Versus Late Parenteral Nutrition in Critically Ill Adults (EPaNIC) trial and the Early Versus Late Parenteral Nutrition in Critically Ill Children (PEPaNIC) trial, demonstrated harm by early PN. Indeed, in both critically adults and children, when compared with withholding PN for 1 week, early supplemental PN prolonged ICU dependency, with a prolonged need for vital organ support and an increased incidence of new infections. 19, 20 In critically ill adults, early PN also increased the incidence of muscle weakness and hampered recovery hereof. 24 Harm occurred irrespective of the nutrition risk, as estimated by the nutrition risk score, and in all studied patient subgroups. Importantly, the patient subgroups who were presumed to benefit most from early PN, including the youngest children, critically ill children with the greatest nutrition risk and critically ill patients with a contraindication to EN did experience the most harm. 19, 20 Apart from the EPaNIC and PEPaNIC RCTs, 4 other RCTs also found no benefit from early PN in critically ill patients. [21] [22] [23] 68 In the latter RCTs, however, the achieved difference in energy intake between both groups was smaller than in EPaNIC and PEPaNIC trials. Hence, studies investigating the impact of early vs late initiation of supplemental PN found that early supplemental PN did not benefit critically ill patients and may induce harm.
Theoretically, the harm induced by early supplemental PN could be explained by a different feeding route or by a different nutrition dose. Recently, 2 large RCTs randomizing patients to early EN or early PN could not detect significant harm by early PN, with an isocaloric amount of feeding in both groups. 25, 26 Noteworthy, both studies challenge the dogma that EN would preserve intestinal integrity. 27, 28 Indeed, administering early EN to severely ill patients increased the risk of intestinal ischemia, a highly lethal complication, as well as diarrhea and acute colonic pseudo-obstruction. 26 Nevertheless, the results from both RCTs suggest that the harm observed in the EPANIC and PEPaNIC RCTs is explained by a different feeding dose rather than by a different route of feeding. This is supported by a secondary analysis of the EPaNIC study, which revealed a dose-dependent impact of feeding on outcome. Indeed, in this study, the lowest macronutrient dose independently associated with the fastest recovery, irrespective of the route of feeding. 29 Consistent with this, several recent RCTs have confirmed no clinical benefit with providing a higher nutrition dose through EN or with an intensified nutrition regimen. [30] [31] [32] [33] [34] [35] Moreover, several of these trials even suggested potential harm by providing a higher dose of feeding. 32, 34, 35 Likewise, in patients developing refeeding syndrome after initiation of artificial feeding, nutrient restriction dramatically improved survival. 36 Of note, a recent observational study found that patients developing refeeding syndrome could not be identified in advance, which broadens caution not to advance nutrition too aggressively to all ICU patients. 37 Several experts have attributed the neutral or negative impact of early enhanced feeding in RCTs to the relatively low amount of administered proteins. [38] [39] [40] However, 1 recent RCT that specifically evaluated a higher vs lower protein dose failed to demonstrate a beneficial impact of a higher protein dose. 41 A second criticism raised was that the feeding target was mostly not individualized. Indeed, several experts have suggested that the feeding target should be determined by indirect calorimetry rather than by a formula. 6, 9, 40 Nevertheless, 3 recent RCTs that used indirect calorimetry in the intervention group did not find any benefit of such strategy. 21, 23, 35 Moreover, aggregating the results of these trials suggested that individualized nutrition, which led to an increased feeding dose, was ineffective. 21, 23, 35, 42 In conclusion, recent nutrition RCTs in critically ill patients, altogether involving >15,000 patients, found that early full nutrition support did not benefit ICU patients and may induce harm.
Mechanisms Explaining Why Early Feeding Has Failed to Benefit Patients
Mechanistic studies have indicated several potential mechanisms why early full nutrition support has failed to improve outcome: failure to suppress endogenous catabolism and feeding-induced suppression of autophagy.
In a preplanned substudy of the EPaNIC trial, early PN was found unable to suppress both microscopic and macroscopic muscle loss. 24, 43 Indeed, early PN failed to suppress the ubiquitin-proteasome system and did not improve markers of muscular protein synthesis. Consequently, irrespective of the nutrition regimen, the myofiber crosssectional area, assessed microscopically, and the femoral muscle compartment, assessed by repetitive computed tomography scans, were equally reduced when compared with healthy controls. Moreover, of the supplementary amino acids given by early PN, almost two thirds were net wasted in urea, which may have prolonged the duration of renal replacement therapy. 44 Similarly, in the PEPaNIC study, urea levels significantly increased by administering early PN, with an increased need for renal replacement therapy. 20, 45 Likewise, the Intravenous Amino Acid Therapy for Kidney Function in Critically Ill and (Nephro-Protective) the Early Goal-Directed Nutrition Versus Standard of Care in Adult Intensive Care Patients (EAT-ICU) trials revealed increased ureagenesis by giving more amino acids. 23, 41 Apart from the inefficient suppression of muscle wasting, feeding-induced suppression of autophagy has emerged as a potential mechanism explaining harm by early PN. Autophagy was first described by Christian De Duve and has long been considered to be a cell death pathway, apart from necrosis and apoptosis. 46, 47 However, whether autophagic cell death really exists remains controversial. Indeed, the presence of autophagosomes in dying cells is not a proof of autophagy-mediated cell death because cells can be dying despite autophagy rather than because of autophagy. Moreover, the genetic inhibition of autophagy facilitates rather than inhibits cell death, which supports a prosurvival function of autophagy. 47 Currently, autophagy is considered to be an important housekeeping process, which is, among others, the only process able to clear intracellular microorganisms and macromolecular damage, including damaged organelles and protein aggregates. In the past 2 decades, increasing evidence has demonstrated a protective role of autophagy in various diseases, including critical illness. [48] [49] [50] [51] [52] The process starts with the formation of isolation membranes in the cytoplasm, which elongate to ultimately form autophagosomes (Figure 1 ). During the elongation process, substrate is recruited to the growing autophagosome. Mature autophagosomes finally fuse with lysosomes, resulting in digestion of the sequestered substrate. 53, 54 Autophagy is highly regulated, with nutrient restriction being one of the most potent stimulators. Apart from that, other relevant activators of autophagy include inflammation, hypoxia/ischemia, endoplasmic reticulum stress, oxidative stress, and mitochondrial damage. 55 Conversely, nutrients, especially amino acids, and insulin and other growth factors are potent suppressors of autophagy. 54 Recent evidence puts forward a crucial role of autophagy activation in the recovery from a lifethreatening insult. 53 Indeed, in animal models, active autophagy protected against sepsis-induced organ failure and mortality as well as against toxic liver and kidney injury and against ischemia-reperfusion injury in various organs. 53 Observational studies in critically ill patients support a crucial role of autophagy in mediating organ recovery. In liver and muscle biopsies of prolonged critically ill patients who died in the intensive care unit with persistent organ failure and/or muscle weakness, an autophagy deficiency phenotype was observed, with an accumulation of autophagic substrate in the presence of a reduced number of autophagic vacuoles. recent evidence supports a role of feeding-induced suppression of autophagy in mediating the adverse outcomes provoked by early PN. Indeed, in a randomized controlled animal study, when compared with relative starvation, full feeding suppressed autophagy in liver and muscle, accompanied by increased liver damage markers and increased muscle degeneration. 50 In this study, the feeding-induced suppression of autophagy and related organ damage was most severe in animals receiving amino acid-enriched nutrition, more than lipid-enriched or glucose-enriched nutrition. These findings were subsequently confirmed in critically ill patients. Indeed, in muscle biopsies of a subgroup of patients randomized in the EPaNIC study, patients randomized to early PN had significantly less activation of autophagy in muscle when compared with patients having a late initiation of PN. Importantly, autophagy suppression in muscle was accompanied with an increased incidence of muscle weakness and a hampered recovery hereof. In addition, in multivariate analysis, a molecular marker of autophagy activation independently associated impaired autophagy with more muscle weakness. 56 Moreover, in a second patient study, the cumulative amount of amino acids until the time of biopsy correlated with increased suppression of autophagy in muscle. 52 Altogether, these studies suggest that the harmful impact of early PN, as observed in the EPaNIC and PEPaNIC studies, is at least partially explained by feeding-induced suppression of autophagy, which leads to an impaired clearance of cellular damage (Figure 2) . The strong suppressive effect of amino acids on autophagy may explain why secondary analyses of the EPaNIC and PEPaNIC studies statistically attributed the harm by giving early PN to the increased amino acid dose, and not to the other macronutrients. 29, 45 Altogether, the current evidence may suggest that the anorexia in- duced by any acute, severe illness is an adaptive response and hence beneficial in the acute phase by activating autophagy.
Several authors have advocated against a protective role of autophagy in critical illness. 57, 58 Their main argument is the absence of a positive impact of glutamine administration in critical illness (Table 2 ) despite the potential autophagy-activating properties of glutamine. 59 However, in critical illness, the impact of glutamine on autophagy has never been investigated. Moreover, evidence exists that also glutamine deprivation may activate autophagy. 60 Hence, the negative impact of glutamine administration in clinical studies cannot be used as argument against autophagy activation as essential recovery process in critical illness. 
Clinical Exploitment of Autophagy
Theoretically, apart from nutrient restriction, autophagy could also be activated through pharmacological intervention. In this regard, an animal study has shown that the feeding-induced suppression of autophagy could be overcome by the autophagy activator rapamycin, which simultaneously improved organ function and protected against bone loss. 51, 61 Apart from its powerful impact on autophagy, however, rapamycin has potent immunesuppressive effects, which precludes its use as autophagy activator in critically ill patients. Likewise, other registered drugs with autophagy-stimulating potential have other important pharmacological effects. 62, 63 Unfortunately, no specific autophagy activators are available for clinical use at present.
In addition, in vivo monitoring of autophagy is problematic, as this requires extensive laboratory testing and repetitive biopsies. 64 Although autophagy monitoring on white blood cells could be a readout for the autophagy status in other organs, this has not been validated in critically ill patients. 65 Moreover, the activation status of autophagy may slightly differ between organs.
66,67

Conclusion
In conclusion, several recent large RCTs have shown that early full nutrition support does not benefit critically ill patients and may induce harm. Mechanistic studies attributed the observed harm to feeding-induced suppression of autophagy, a repair process that was found to be crucial in animal models to recover from critical insults. Future research should aim at developing specific autophagy activators, which are needed before clinical studies can be initiated. Currently, autophagy cannot be monitored in clinical practice. However, clinical management should be guided by high quality RCTs. These studies do not support early full nutrition support to critically ill patients.
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